That Biologics center has seen 106 departures since the beginning of the year. That's on top of about 150 RIFs that were also part of that center. If you look at The drug center lost about a third of the reviewers that review breast and gynecological cancer products. They lost more than half of the group that reviews malignant heme products. They've seen 473 departures of medical reviewers, voluntary departures, on top of about 600 RIFs. (07:49–07:57)
CLAIM
Asserts that the drug center lost about a third of its reviewers for breast and gynecological cancer products.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
